The Wistar Institute

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Active Biotech Ab

Dmitry Gabrilovich

Scott Antonia

Claudio Anasetti

Frederick L Locke

David Liberg

Dario C Altieri

Helena Eriksson

Marie Törngren

Anders Olsson

Yuliya Nefedova

Thomas C Condamine

Fabien Schmidlin

Dario Altieri

The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.

Variant survivin vaccine for treatment of myeloma

Provided herein are methods of generating MDSCs ex vivo. The methods include culturing blood cells with lactoferrin.

Use of lactoferrin for generating myeloid-derived suppressor cells

Provided herein are methods of generating MDSCs ex vivo. The methods include culturing blood cells with an LRP2 agonist.

Use of LRP2 agonists for generating myeloid-derived suppressor cells

A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) comprises isolating from a cell suspension those cells which express LOX-1 to provide a population of cells enriched with PMN-MDSCs. A method of monitoring the population of LOX-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. Other cell isolation and diagnostic methods are also described.

Methods for monitoring polymorphonuclear myeloid derived suppressor cells

Double mutant survivin vaccine

A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.

Quinoline carboxamides for use in the treatment of multiple myeloma

A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma. 

Growing community of inventors

Villanova, PA, United States of America

Dmitry Gabrilovich